Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUO6XC)

Drug Name

VCB101 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Preclinical	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Cysteines of Keap1 (KEAP1 Cysteines)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CXA10	DMM7Z6K	Focal segmental glomerulosclerosis	MF8Y	Phase 2	[3]
PMID28454500-Compound-8	DM6BQFA	N. A.	N. A.	Patented	[4]
Pyrazino[2,1-a]isoquinolin derivative 4	DMKTNBC	N. A.	N. A.	Patented	[4]
PMID28454500-Compound-36	DM5RZWG	N. A.	N. A.	Patented	[4]
Chalcone derivative 4	DM45COR	N. A.	N. A.	Patented	[4]
2-hydroxybenzamide derivative 1	DMER2ZQ	N. A.	N. A.	Patented	[4]
Vinyl sulfone derivative 1	DMTMFNK	N. A.	N. A.	Patented	[4]
Pyrazino[2,1-a]isoquinolin derivative 2	DMYXKQ3	N. A.	N. A.	Patented	[4]
Diterpenoid derivative 1	DMAZOH4	N. A.	N. A.	Patented	[4]
PMID28454500-Compound-13	DM7SIVA	N. A.	N. A.	Patented	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cysteines of Keap1 (KEAP1 Cysteines)	TT3Z6Y9	KEAP1_HUMAN	Inactivator	[2]

------------------------------------------------------------------------------------

References

1	Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317.
2	NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases. Biomolecules. 2020 Jun 14;10(6):904.
3	The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56.
4	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785.